Who's Watching Alexion Now?

1 2 3 4
Part 3
Who's Watching Alexion Now? PART 3 OF 4

Gauging Alexion’s 2018 Growth with Soliris

Soliris’s revenue trends

In 2Q17, Alexion Pharmaceuticals’ (ALXN) Soliris generated revenues of ~$814 million, which represented a ~16% YoY (year-over-year) rise and a ~4% QoQ (quarter-over-quarter) rise. In 1H17, Soliris reported revenues of ~$1.6 billion, compared with $1.37 billion in 1H16.

In 1H17, in US markets, Soliris saw revenues of ~$606 million, or ~22% higher on a YoY basis. In 1H17, in Europe, Asia-Pacific, and the rest of the world, Soliris reported revenues of ~$490 million, $160 million, and $341 million, respectively, which represented rises of ~6%, ~12%, and 30%, respectively, YoY.

Gauging Alexion&#8217;s 2018 Growth with Soliris

Interested in ALXN? Don't miss the next report.

Receive e-mail alerts for new research on ALXN

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

In 2Q17, in the US, Europe, Asia-Pacific, and the rest of the world, Soliris reported revenues of ~$318 million, ~$249 million, ~$81 million, and ~$166 million, respectively, which represented rises of ~22%, ~4%, ~9% and ~31%, respectively, YoY.

Alexion anticipates that GAAP (generally accepted accounting principles) net revenues from the sale of Solaris in 2017 will be in the range of $3.08 billion–$3.13 billion.

About Soliris

The USPTO (US Patent and Trademark Office) granted three new patent protections to Soliris up to 2027. The USPTO issued three US patents related to the composition of Soliris (eculizumab), a pharmaceutical formulation of eculizumab, and a method of treating paroxysmal nocturnal hemoglobinuria to Soliris. These patents will expire in 2027 and are expected to strengthen ALNX’s intellectual property portfolio.

In September 2017, Alexion presented the results of the interim analysis of a phase-3 open-label extension trial, which demonstrated consistent clinical benefits of Soliris for the treatment of individuals with refractory generalized myasthenia gravis, based on the results of its Regain extension study.

For 52 weeks, patients who continued to receive Soliris and patients who shifted from placebo treatment in the Regain trial to Soliris treatment in the extension study demonstrated significant rapid and consistent improvements.

Alexion’s peers in the orphan drug market include Vertex Pharmaceuticals (VRTX), Shire Pharmaceuticals, Amgen (AMGN), Novartis (NVS), and BioMarin Pharmaceuticals. The PowerShares QQQ (QQQ) has ~0.47% of its total portfolio holdings in ALXN.


Please select a profession that best describes you: